Data availability
Ribo-seq, RNA-seq and tRNA-seq used in this study can be accessed under SRA BioProject accession numbers PRJNA1355021, PRJNA1355053, PRJNA1468319, PRJNA1468382 and PRJNA1499311. The MS proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD076465. Source data are provided with this paper.
Code availability
The code for data processing and analysis in bioinformatics is fully referenced and described in the Methods. The code for out-of-frame translation based on Ribo-seq is available at GitHub (https://github.com/YHMao-Ribo/FS_from_Ribo) and archived on Zenodo83 (https://doi.org/10.5281/zenodo.20035132).
References
Hill, C. H. & Brierley, I. Structural and functional insights into viral programmed ribosomal frameshifting. Annu. Rev. Virol. 10, 217–242 (2023).
Article CAS PubMed PubMed Central Google Scholar
Caliskan, N., Peske, F. & Rodnina, M. V. Changed in translation: mRNA recoding by −1 programmed ribosomal frameshifting. Trends Biochem. Sci. 40, 265–274 (2015).
Article CAS PubMed PubMed Central Google Scholar
Cochella, L. & Green, R. Fidelity in protein synthesis. Curr. Biol. 15, R536–R540 (2005).
Article CAS PubMed Google Scholar
Zaher, H. S. & Green, R. Fidelity at the molecular level: lessons from protein synthesis. Cell 136, 746–762 (2009).
Article CAS PubMed PubMed Central Google Scholar
Kelly, J. A. & Dinman, J. D. Shiftless is a novel member of the ribosome stress surveillance machinery that has evolved to play a role in innate immunity and cancer surveillance. Viruses 15, 2296 (2023).
Article CAS PubMed PubMed Central Google Scholar
Stein, K. C. & Frydman, J. The stop-and-go traffic regulating protein biogenesis: how translation kinetics controls proteostasis. J. Biol. Chem. 294, 2076–2084 (2019).
Article CAS PubMed Google Scholar
Choe, Y.-J. et al. Failure of RQC machinery causes protein aggregation and proteotoxic stress. Nature 531, 191–195 (2016).
Article ADS CAS PubMed Google Scholar
Zhang, Y. et al. Ribosomes modulate transcriptome abundance via generalized frameshift and out-of-frame mRNA decay. Mol. Cell 85, 2017–2031 (2025).
Article CAS PubMed Google Scholar
Belew, A. T. et al. Ribosomal frameshifting in the CCR5 mRNA is regulated by miRNAs and the NMD pathway. Nature 512, 265–269 (2014); retraction https://doi.org/10.1038/s41586-026-11149-4 (2026).
Article ADS CAS PubMed Google Scholar
Plant, E. P., Wang, P., Jacobs, J. L. & Dinman, J. D. A programmed –1 ribosomal frameshift signal can function as a cis-acting mRNA destabilizing element. Nucleic Acids Res. 32, 784–790 (2004).
Article CAS PubMed PubMed Central Google Scholar
Belew, A. T., Advani, V. M. & Dinman, J. D. Endogenous ribosomal frameshift signals operate as mRNA destabilizing elements through at least two molecular pathways in yeast. Nucleic Acids Res. 39, 2799–2808 (2011).
Article CAS PubMed Google Scholar
Rodnina, M. V. Decoding and recoding of mRNA sequences by the ribosome. Annu. Rev. Biophys. 52, 161–182 (2023).
Article CAS PubMed Google Scholar
Dever, T. E., Dinman, J. D. & Green, R. Translation elongation and recoding in eukaryotes. Cold Spring Harb. Perspect. Biol. 10, a032649 (2018).
Article PubMed PubMed Central Google Scholar
Bartok, O. et al. Anti-tumour immunity induces aberrant peptide presentation in melanoma. Nature 590, 332–337 (2021).
Article ADS CAS PubMed Google Scholar
Champagne, J. et al. Oncogene-dependent sloppiness in mRNA translation. Mol. Cell 81, 4709–4721 (2021).
Article CAS PubMed Google Scholar
Kochavi, A. et al. Chemotherapeutic agents and leucine deprivation induce codon-biased aberrant protein production in cancer. Nucleic Acids Res. 52, 13964–13979 (2024).
Article CAS PubMed PubMed Central Google Scholar
Weller, C. et al. Translation dysregulation in cancer as a source for targetable antigens. Cancer Cell 43, 823–840 (2025).
Article CAS PubMed PubMed Central Google Scholar
Guertin, D. A. & Sabatini, D. M. Defining the role of mTOR in cancer. Cancer Cell 12, 9–22 (2007).
Article CAS PubMed Google Scholar
Downward, J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3, 11–22 (2003).
Article CAS PubMed Google Scholar
Chen, A. X. Y. et al. Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery. Nature 644, 241–251 (2025).
Article ADS CAS PubMed PubMed Central Google Scholar
Mao, Y., Jia, L., Dong, L., Shu, X. E. & Qian, S.-B. Start codon-associated ribosomal frameshifting mediates nutrient stress adaptation. Nat. Struct. Mol. Biol. 30, 1816–1825 (2023).
Article CAS PubMed Google Scholar
Lindsley, D. & Gallant, J. On the directional specificity of ribosome frameshifting at a “hungry” codon. Proc. Natl Acad. Sci. USA 90, 5469–5473 (1993).
Article ADS CAS PubMed PubMed Central Google Scholar
Ren, G. et al. Ribosomal frameshifting at normal codon repeats recodes functional chimeric proteins in human. Nucleic Acids Res. 52, 2463–2479 (2024).
Article CAS PubMed PubMed Central Google Scholar
Kesner, J. S. et al. Noncoding translation mitigation. Nature 617, 395–402 (2023).
Article ADS CAS PubMed PubMed Central Google Scholar
Müller, M. B., Kasturi, P., Jayaraj, G. G. & Hartl, F. U. Mechanisms of readthrough mitigation reveal principles of GCN1-mediated translational quality control. Cell 186, 3227–3244 (2023).
Article PubMed PubMed Central Google Scholar
Supek, F., Lehner, B. & Lindeboom, R. G. To NMD or not to NMD: nonsense-mediated mRNA decay in cancer and other genetic diseases. Trends Genet. 37, 657–668 (2021).
Article CAS PubMed Google Scholar
Schwanhäusser, B. et al. Global quantification of mammalian gene expression control. Nature 473, 337–342 (2011).
Article ADS PubMed Google Scholar
Tani, H. et al. Genome-wide determination of RNA stability reveals hundreds of short-lived noncoding transcripts in mammals. Genome Res. 22, 947–956 (2012).
Article CAS PubMed PubMed Central Google Scholar
Farabaugh, P. J. Programmed translational frameshifting. Microbiol. Rev. 60, 103–134 (1996).
Article CAS PubMed PubMed Central Google Scholar
Kawakami, K. et al. A rare tRNA-Arg(CCU) that regulates Ty1 element ribosomal frameshifting is essential for Ty1 retrotransposition in Saccharomyces cerevisiae. Genetics 135, 309–320 (1993).
Article CAS PubMed PubMed Central Google Scholar
Belcourt, M. F. & Farabaugh, P. J. Ribosomal frameshifting in the yeast retrotransposon Ty: tRNAs induce slippage on a 7 nucleotide minimal site. Cell 62, 339–352 (1990).
Article CAS PubMed PubMed Central Google Scholar
Farabaugh, P. J., Zhao, H. & Vimaladithan, A. A novel programed frameshift expresses the POL3 gene of retrotransposon Ty3 of yeast: frameshifting without tRNA slippage. Cell 74, 93–103 (1993).
Article CAS PubMed PubMed Central Google Scholar
Simms, C. L., Yan, L. L., Qiu, J. K. & Zaher, H. S. Ribosome collisions result in +1 frameshifting in the absence of no-go decay. Cell Rep. 28, 1679–1689 (2019).
Article CAS PubMed PubMed Central Google Scholar
Tu, C., Tzeng, T. H. & Bruenn, J. A. Ribosomal movement impeded at a pseudoknot required for frameshifting. Proc. Natl Acad. Sci. USA 89, 8636–8640 (1992).
Article ADS CAS PubMed PubMed Central Google Scholar
Namy, O., Moran, S. J., Stuart, D. I., Gilbert, R. J. & Brierley, I. A mechanical explanation of RNA pseudoknot function in programmed ribosomal frameshifting. Nature 441, 244–247 (2006).
Article ADS CAS PubMed PubMed Central Google Scholar
Chen, J. et al. Dynamic pathways of –1 translational frameshifting. Nature 512, 328–332 (2014).
Article ADS CAS PubMed PubMed Central Google Scholar
Yan, S., Wen, J. D., Bustamante, C. & Tinoco, I. Jr. Ribosome excursions during mRNA translocation mediate broad branching of frameshift pathways. Cell 160, 870–881 (2015).
Article CAS PubMed PubMed Central Google Scholar
Caliskan, N., Katunin, V. I., Belardinelli, R., Peske, F. & Rodnina, M. V. Programmed −1 frameshifting by kinetic partitioning during impeded translocation. Cell 157, 1619–1631 (2014).
Article CAS PubMed PubMed Central Google Scholar
Filbeck, S., Cerullo, F., Pfeffer, S. & Joazeiro, C. A. Ribosome-associated quality-control mechanisms from bacteria to humans. Mol. Cell 82, 1451–1466 (2022).
Article CAS PubMed PubMed Central Google Scholar
Inada, T. & Beckmann, R. Mechanisms of translation-coupled quality control. J. Mol. Biol. 436, 168496 (2024).
Article CAS PubMed Google Scholar
Guydosh, N. R. & Green, R. Dom34 rescues ribosomes in 3’ untranslated regions. Cell 156, 950–962 (2014).
Article CAS PubMed PubMed Central Google Scholar
Wu, C. C.-C., Zinshteyn, B., Wehner, K. A. & Green, R. High-resolution ribosome profiling defines discrete ribosome elongation states and translational regulation during cellular stress. Mol. Cell 73, 959–970 (2019).
Article CAS PubMed PubMed Central Google Scholar
Juszkiewicz, S. et al. ZNF598 is a quality control sensor of collided ribosomes. Mol. Cell 72, 469–481 (2018).
Article CAS PubMed PubMed Central Google Scholar
Sundaramoorthy, E. et al. ZNF598 and RACK1 regulate mammalian ribosome-associated quality control function by mediating regulatory 40S ribosomal ubiquitylation. Mol. Cell 65, 751–760 (2017).
Article CAS PubMed PubMed Central Google Scholar
Garzia, A. et al. The E3 ubiquitin ligase and RNA-binding protein ZNF598 orchestrates ribosome quality control of premature polyadenylated mRNAs. Nat. Commun. 8, 16056 (2017).
Article ADS CAS PubMed PubMed Central Google Scholar
Fabbri, L., Chakraborty, A., Robert, C. & Vagner, S. The plasticity of mRNA translation during cancer progression and therapy resistance. Nat. Rev. Cancer 21, 558–577 (2021).
Article CAS PubMed Google Scholar
Cherkaoui, S. et al. Reprogramming neuroblastoma by diet-enhanced polyamine depletion. Nature 646, 707–715 (2025).
Article ADS CAS PubMed PubMed Central Google Scholar
Loayza-Puch, F. et al. Tumour-specific proline vulnerability uncovered by differential ribosome codon reading. Nature 530, 490–494 (2016).
Article ADS CAS PubMed Google Scholar
Ruvinsky, I. & Meyuhas, O. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem. Sci 31, 342–348 (2006).
Article CAS PubMed Google Scholar
Shi, J. et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526, 660–665 (2015).
Article ADS CAS PubMed Google Scholar
Lieberman, J., Wu, H. & Kagan, J. C. Gasdermin D activity in inflammation and host defense. Sci. Immunol. 4, eaav1447 (2019).
Article CAS PubMed PubMed Central Google Scholar
Fontana, P. et al. Small-molecule GSDMD agonism in tumors stimulates antitumor immunity without toxicity. Cell 187, 6165–6181 (2024).
Article CAS PubMed PubMed Central Google Scholar
Zhang, Z. et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature 579, 415–420 (2020).
Article ADS CAS PubMed PubMed Central Google Scholar
Sharma, P. et al. Immune checkpoint therapy-current perspectives and future directions. Cell 186, 1652–1669 (2023).
Article ADS CAS PubMed Google Scholar
Storz, P. & Crawford, H. C. Carcinogenesis of pancreatic ductal adenocarcinoma. Gastroenterology 158, 2072–2081 (2020).
Article CAS PubMed PubMed Central Google Scholar
Rhim, A. D. et al. EMT and dissemination precede pancreatic tumor formation. Cell 148, 349–361 (2012).
Article CAS PubMed PubMed Central Google Scholar
Ho, W. J. et al. Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways. Genome Biol. 22, 154 (2021).
Article CAS PubMed PubMed Central Google Scholar
Raghavan, S. et al. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell 184, 6119–6137 (2021).
Article CAS PubMed PubMed Central Google Scholar
Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. Cell 169, 361–371 (2017).
Article ADS CAS PubMed Google Scholar
Carmody, P. J. et al. Ribosomal frameshifting selectively modulates the assembly, function, and pharmacological rescue of a misfolded CFTR variant. Proc. Natl Acad. Sci. USA 121, e2414768121 (2024).
Article CAS PubMed PubMed Central Google Scholar
Sinha, N. K. et al. EDF1 coordinates cellular responses to ribosome collisions. eLife 9, e58828 (2020).
Article CAS PubMed PubMed Central Google Scholar
Misra, J. et al. Discordant regulation of eIF2 kinase GCN2 and mTORC1 during nutrient stress. Nucleic Acids Res. 49, 5726–5742 (2021).
Article CAS PubMed PubMed Central Google Scholar
Wang, Q. et al. Bmi-1 overexpression improves sarcopenia induced by 1,25(OH)2D3 deficiency and downregulates GATA4-dependent Rela transcription. J. Bone Miner. Res. 38, 427–442 (2023).
Article CAS PubMed Google Scholar
Zhou, J. et al. Sirt1 overexpression improves senescence-associated pulmonary fibrosis induced by vitamin D deficiency through downregulating IL-11 transcription. Aging Cell 21, e13680 (2022).
Article CAS PubMed PubMed Central Google Scholar
Liu, L. et al. Myocardin-related transcription factor A (MRTF-A) contributes to acute kidney injury by regulating macrophage ROS production. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 3109–3121 (2018).
Article CAS PubMed Google Scholar
Wu, J. et al. EFHD2 suppresses intestinal inflammation by blocking intestinal epithelial cell TNFR1 internalization and cell death. Nat. Commun. 15, 1282 (2024).
Article ADS CAS PubMed PubMed Central Google Scholar
Fan, Z. et al. An interaction between MKL1, BRG1, and C/EBPβ mediates palmitate induced CRP transcription in hepatocytes. Biochim. Biophys. Acta Gene Regul. Mech. 1862, 194412 (2019).
Article CAS PubMed Google Scholar
Yang, G. et al. The histone H3K9 methyltransferase SUV39H links SIRT1 repression to myocardial infarction. Nat. Commun. 8, 14941 (2017).
Article ADS CAS PubMed PubMed Central Google Scholar
Loughran, G. et al. Guidelines for minimal reporting requirements, design and interpretation of experiments involving the use of eukaryotic dual gene expression reporters (MINDR). Nat. Struct. Mol. Biol. 32, 418–430 (2025).
Article CAS PubMed PubMed Central Google Scholar
Mikl, M., Pilpel, Y. & Segal, E. High-throughput interrogation of programmed ribosomal frameshifting in human cells. Nat. Commun. 11, 3061 (2020).
Article ADS CAS PubMed PubMed Central Google Scholar
Devant, P. et al. Gasdermin D pore-forming activity is redox-sensitive. Cell Rep. 42, 112008 (2023).
Article CAS PubMed PubMed Central Google Scholar
Wang, J. et al. AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice. Nature 604, 343–348 (2022).
Article ADS CAS PubMed PubMed Central Google Scholar
Roux, P. P. et al. RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J. Biol. Chem. 282, 14056–14064 (2007).
Article CAS PubMed PubMed Central Google Scholar
Fu, J. et al. mRNA lipid-nanoparticle-mediated mitochondrial apoptosis augments adoptive T cell immunotherapy. Cell Rep. Med. 7, 102706 (2026).
Article CAS PubMed PubMed Central Google Scholar
Kolakada, D. et al. Systematic analysis of nonsense variants uncovers peptide release rate as a novel modifier of nonsense-mediated mRNA decay. Cell Genom. 5, 100882 (2025).
Article CAS PubMed PubMed Central Google Scholar
Cozen, A. E. et al. ARM-seq: AlkB-facilitated RNA methylation sequencing reveals a complex landscape of modified tRNA fragments. Nat. Methods 12, 879–884 (2015).
Article CAS PubMed PubMed Central Google Scholar
Demichev, V., Messner, C. B., Vernardis, S. I., Lilley, K. S. & Ralser, M. DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput. Nat. Methods 17, 41–44 (2020).
Article CAS PubMed Google Scholar
Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 17, 10–12 (2011).
Article Google Scholar
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
Article CAS PubMed Google Scholar
Luo, S. et al. Unconventional codon usage bias mediates mRNA translational dynamics in macrophages. PLoS Biol. 23, e3003403 (2025).
Article CAS PubMed PubMed Central Google Scholar
Behrens, A., Rodschinka, G. & Nedialkova, D. D. High-resolution quantitative profiling of tRNA abundance and modification status in eukaryotes by mim-tRNAseq. Mol. Cell 81, 1802–1815 (2021).
Article CAS PubMed PubMed Central Google Scholar
Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359 (2012).
Article CAS PubMed PubMed Central Google Scholar
Wang, Q. et al. Code for ‘Cancer-selective gene circuits via intrinsic ribosomal frameshifting’. Zenodo https://doi.org/10.5281/zenodo.20035132 (2026).
Download references
Acknowledgements
We thank H. Ouyang and W. Mo for discussions on the topic; and the members of the Liangzhu Laboratory Core Facilities for technical support.
Funding
This work was supported by grants from the National Key Research and Development Program of China (2025YFA1308700, Y.M.), the National Natural Science Foundation of China (32370585, Y.M.), the Zhejiang Provincial Natural Science Foundation of China (LZ26C060002, Y.M.), the Zhejiang Provincial Leading Innovation and Entrepreneurship Team Introduction and Cultivation Program (2024R01024, Y.M.) and the Key Research and Development Program of Zhejiang Province (2024SSYS0025, Y.M.).
Author information
Authors and Affiliations
Department of Urology of The Second Affiliated Hospital of Medicine & Liangzhu Laboratory, Zhejiang University, Hangzhou, China
Qiuyi Wang, Ao Chen, Pengyu Chen & Yuanhui Mao
Liangzhu Laboratory, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China
Qiuyi Wang, Ao Chen, Xiaoxiao Yu, Hao Zhang, Pengyu Chen, Yue Zhang, Francis Ka-Ming Chan & Yuanhui Mao
Institute of Biochemistry, College of Life Sciences, Zhejiang University, Hangzhou, China
Yaoqi Liu
Department of Cardiology of The Second Affiliated Hospital of Medicine, Zhejiang University, Hangzhou, China
Yuqiang Yu & Francis Ka-Ming Chan
Department of Clinical Laboratory of Sir Run Run Shaw Hospital, and School of Public Health, Zhejiang University School of Medicine, Hangzhou, China
Xiangwei Gao
Authors
- Qiuyi Wang
- Ao Chen
- Yaoqi Liu
- Xiaoxiao Yu
- Hao Zhang
- Yuqiang Yu
- Pengyu Chen
- Yue Zhang
- Francis Ka-Ming Chan
- Xiangwei Gao
- Yuanhui Mao
Contributions
Y.M. and X.G. conceived and supervised the study. Y.M. designed and performed the computational analyses and wrote the manuscript. Q.W. conducted the majority of the experiments. A.C. and P.C. optimized the Ribo-seq pipeline. P.C. conducted experiments involving construct preparation and luciferase activity analysis. X.Y., H.Z. and Y.Z. assisted with AAV9 experiments. Y.Y. and F.K.-M.C. contributed to the design of the FAST construct. Y.L. provided technical support for plasmid preparation and animal work. F.K.-M.C. and X.G. provided overall guidance and critical revision of the manuscript. All of the authors discussed the results and approved the final version of the paper.
Corresponding author
Correspondence to Yuanhui Mao.
Ethics declarations
Competing interests
The Liangzhu laboratory has filed a Chinese patent application related to this work (application no. 202611056808.0; status: pending), claiming priority from 31 October 2025. Y.M. and Q.W. are listed as inventors. The application covers designed ribosomal frameshifting motifs and their use in frameshift-activated gene circuits for selective therapeutic targeting of cancer cells. The other authors declare no competing interests.
Peer review
Peer review information
Nature thanks Jonathan Dinman and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data figures and tables
Extended Data Fig. 1 Analysis of ribosomal frameshifting in cancer cells.
a, Schematic of the dual-luciferase reporters used to quantify +1 and −1 ribosomal frameshifting activity, together with the corresponding control constructs. b, Histogram showing the distribution of read counts for the +1 and −1 frame reporter libraries. c, Nucleotide frequency across the randomized 10-nt insert sequences in the reporter library. d, Quantification of +1 frameshifting activity across multiple cancer cell lines using 10-nt randomized dual-luciferase reporters. “Ctrl” denotes a control reporter lacking an inserted sequence. e, Quantification of −1 frameshifting activity across multiple cancer cell lines using 6-nt randomized dual-luciferase reporters. “Ctrl” denotes a control reporter lacking an inserted sequence. f, Quantification of frameshifting activity for positive-control constructs transfected into HEK293T cells using dual-luciferase reporters containing known frameshifting elements. g, Correlation between out-of-frame rates estimated from Ribo-seq and mean frameshifting activities measured by dual-luciferase reporters in f. h, Heatmap showing in-frame rates for codon pairs across the Ribo-seq dataset. i, Aggregation plots displaying in-frame rates and −1 frame rates before and after codon pairs. “Low” indicates the bottom 10% of codon pairs (n = 372 pairs). “Low-Rev”: codon pairs identical to those in the “Low” group, but with the order of the two codons reversed. j, Scatter plot showing the correlation between Fluc/Rluc ratios and Ribo-seq-derived −1-frame rates. 29 codon pairs were randomly selected, inserted into dual-luciferase reporters and quantified for frameshifting activity. In d–e, data are mean ± s.d.; n = 3 biologically independent samples. In f–g, data are mean ± SEM; n = 4 biologically independent samples. In g and j, Pearson’s correlation coefficients were calculated and two-sided P values are shown.
Source data
Extended Data Fig. 2 Characterization of frameshifting on codon pairs.
a, Frame analysis of Ribo-seq, with the majority of datasets showing in-frame rate higher than 70%. b, Frameshifting activity of individual codon pairs in HCT116 cells. A single codon pair was inserted between Rluc and Fluc in the dual-luciferase reporter, with Fluc placed in the −1 frame relative to Rluc. Numbers on the bars refer to average values (%) of the three replicates. Although a single codon pair is sufficient to induce significant frameshifting signals in HCT116 cells, to increase the detectable frameshifting signal in other cells and thereby facilitate analysis of both regulatory mechanisms and anti-tumour effects, we used 5× tandem repeats of the frameshifting motif in this study. c, Comparison of frameshifting activity using different repeat numbers of the frameshifting motif. For the 3×, 5× and 10× constructs, adjacent motifs were separated by a CCC codon. CCC was selected because cytosine-rich spacer sequences are less likely than A-, T- or G-rich spacers to generate premature stop codons (TAA, TAG or TGA) with adjacent sequences, thereby minimizing unintended effects on reporter expression. Numbers on the bars refer to average values (%) of the three replicates. d, Comparison of frameshifting activity when repeated frameshifting motifs were separated by different synonymous proline codons. CCC produced the lowest frameshifting activity, whereas CCG produced the highest. Because CCG is a relatively rare proline codon (RSCU = 0.46) compared with CCC (RSCU = 1.3), these results suggest that spacer codon usage can influence motif activity. In the AGAACG construct separated by CCT, the spacer introduces a − 1 frame stop codon (TAG), thereby terminating −1 frame translation. e, Frameshifting activity in HEK293T and HCT116 cells stably expressing the indicated 5× motif reporter constructs. f, Box plot comparing out-of-frame translation in the +1 and −1 frames between codon pairs with high in-frame rates (top 10%, n = 372 pairs) and low in-frame rates (bottom 10%, n = 372 pairs). Out-of-frame rates are shown relative to the high in-frame group to correct for basal differences in footprint counts across reading frames. g, Comparison of +1 and −1 frameshifting activity in HCT116, PANC-1 and A549 cells. In HCT116 and PANC-1 cells, the frameshifting-prone codon pairs AGAACG and ACGAGA exhibited significantly higher −1 frameshifting activity than the frameshifting-negative control pair CCAAGT, whereas +1 frameshifting at these pairs was low and comparable to CCAAGT. By contrast, in A549 cells, −1 frameshifting was lower than in HCT116 and PANC-1 cells, whereas +1 frameshifting was higher, reaching 2.7% for AGAACG and 1.1% for ACGAGA. h, Analysis as in g using a reporter containing codon pair GGATCC, which showed minimal −1 frameshifting but higher +1 frameshifting. The same CCAAGT control data shown in g are replotted here using a narrower y-axis scale for comparison. In b–e, g and h, data are mean ± s.d.; n = 3 biologically independent samples. In f, boxes show the median and 25th–75th percentiles; whiskers extend to the most extreme values within 1.5× the interquartile range, with outliers shown individually.
Source data
Extended Data Fig. 3 Verification of − 1 ribosomal frameshifting.
a, Fluc/Rluc ratios and corresponding western blots for selected codon pairs tested in HEK293T cells. “uStop” indicates reporters containing a stop codon upstream of the inserted sequence, which terminates translating ribosomes in the upstream region. “dStop” indicates reporters containing a stop codon immediately downstream of the inserted sequence, which terminates −1 frame translation. b, Schematic of the dual-luciferase reporter system used to test for alternative translation initiation or cryptic promoter activity, together with the expected Fluc/Rluc ratios. If Fluc expression were driven by alternative initiation or a cryptic promoter, Fluc activity in the control reporter would be comparable to that in reporters containing the insert. In this study, control reporters showed minimal Fluc activity, suggesting that the observed out-of-frame translation is unlikely to be attributable to spurious initiation or cryptic promoter activity. c, Schematic illustrating potential alternative splicing in the dual-luciferase reporter and the corresponding expected Fluc/Rluc ratios. If Fluc expression resulted from alternative splicing, Fluc activity would be expected to remain detectable in the +1 frame, uStop and dStop reporters, rather than being restricted to the −1 frame reporter. However, these control reporters showed minimal Fluc activity, arguing against alternative splicing as a major contributor. d, RT-PCR analysis of mRNA from dual-luciferase reporters designed to detect aberrant splicing induced by the inserted sequences. Amplified products were resolved by agarose gel electrophoresis and validated by Sanger sequencing. No novel splice junctions were detected near the insertion site, supporting the conclusion that the inserts do not generate new splice donor or acceptor sites. e, Frameshifting activity measured using in vitro-transcribed mRNA reporters. The indicated constructs were transcribed into mRNAs by in vitro transcription and transfected into the indicated cells. Luciferase activity was analysed as for plasmid-based reporters. f, Comparison of frameshifting activity between breast cancer cell lines MDA-MB-231, BT20 and SK-BR-3, and the non-cancerous breast epithelial cell line MCF10A. Numbers on the bars refer to average values (%) of the three replicates. g, Comparison of frameshifting activity between lung cancer cell lines A549, HCC827, and the non-cancerous cell line BEAS-2B. Numbers on the bars refer to average values (%) of the three replicates. h, Comparison of frameshifting activity between liver cancer cell lines Huh-7, HepG2, and the non-cancerous cell line THLE-2. Numbers on the bars refer to average values (%) of the three replicates. In a, e–h, data are mean ± s.d.; n = 3 biologically independent samples; y-axis scales match that for HCT116 cells in Fig. 1g. In a, f–h, western blots were performed once, with concordant findings observed in additional cell lines and related experiments. In d, the experiment was performed once.
Source data
Extended Data Fig. 4 Detection of frameshifting in endogenous-gene-derived sequences.
a, Schematic of the construct used to detect frameshift-derived proteins. The Flag tag is positioned in the −1 reading frame immediately downstream of the AGAACG codons. Note that the Flag sequence lacks a stop codon in either the in-frame or out-of-frame, avoiding premature termination caused by Flag sequence. b, Western blots showing product of frameshifting. The frameshifting codon pair AGAACG within the coding sequence is indicated by a red slash. Coding region is indicated by a blue frame. Lanes 1-4: CCD841, HCT116, SW480, and Caco2 cells without MG132 treatment. Lanes 5-8: CCD841, HCT116, SW480, and Caco2 cells treated with MG132. The numbers in parentheses indicate the length of CDS (nt), and the position of the frameshifting motif within CDS.
Extended Data Fig. 5 Effects of frameshifting on protein expression and mRNA stability.
a, Comparison of ribosome density between mRNAs with or without frameshifting codon pairs. “Codon pairs” denotes the seven frameshifting-positive pairs in Fig. 1. b–d, Same as a, showing mRNA expression, translation efficiency and protein abundance, respectively. e, mRNA stability of transcripts with or without frameshifting pairs in CCD841 and HCT116 cells. f, Gene Ontology pathways enriched among mRNAs containing frameshifting pairs. g,h, RT-qPCR analysis of stability of frameshifting-bearing transcripts TXLNA and PRDX3 after UPF1 knockdown. i, Steady-state abundance of dual-luciferase reporter mRNAs. GFP, expressed in the opposite orientation from the same plasmid, served as an internal control for transfection efficiency. PTC-control contains an NMD-positive element obtained from a previous study75. j–m, Reporter mRNA stability after UPF1 knockdown for PTC-control (j), the frameshifting-negative pair CCAAGT (k), ACGAGA (l) and AGAACG (m). Replacing the frameshifting motif with the canonical NMD-positive element rendered the reporter NMD-sensitive, consistent with sequence-context-dependent modulation of NMD efficiency around premature termination codons75. n–q, Expression of NMD components and ZNF598 in colorectal cancer versus CCD841 cells (n), breast cancer versus MCF10A cells (o), lung cancer versus BEAS-2B cells (p), and liver cancer versus THLE-2 cells (q). In a–e, boxes show the median and 25th–75th percentiles; whiskers extend to the most extreme values within 1.5× the interquartile range, with outliers shown individually. n = 10,634, 3,478, 996, 333, 127 and 83 transcripts for the 0, 1, 2, 3, 4 and ≥5 motif groups, respectively. In g, h and j–m, data are mean ± s.d.; P values correspond to comparisons at the final time point using a two-sided unpaired t-test; n = 3 biologically independent samples. In i, data are mean ± s.d.; n = 3 biologically independent samples. In n–q, western blots show three biologically independent samples per cell line.
Source data
Extended Data Fig. 6 Frameshifting at non-optimal codons is associated with ribosomal pausing and RQC.
a, Relative tRNA abundance in colorectal cancer and non-cancerous CCD841 cells. Values are mean cognate-tRNA abundance for codons within each motif. b, Fold change in tRNA abundance in HCT116 relative to CCD841 (left) or Caco2 (right) cells. c, RT-qPCR analysis of tRNA levels after overexpression of indicated tRNAs in HCT116 or HEK293T cells. d, Frameshifting in HEK293T cells under proline starvation (left) or halofuginone (HF) treatment (right). HF inhibits proline-tRNA aminoacylation, inducing pausing at proline codons62. e, −1 frameshifting using a shortened reporter. Top, reporter schematic; bottom, western blot of frameshift-derived products in HCT116 cells. f, +1 frameshifting using a shortened reporter. Top, HiBiT is positioned in the +1 frame relative to the upstream V5-tagged coding sequence. Bottom, Renilla luciferase activity (transfection control; left) and HiBiT activity (right) after co-transfection in HCT116 cells. g, Modified ribosome-profiling protocol capturing 15–75-nt footprints. h,i, Footprint-length distributions in WT, RPS6 S/D, ZNF598-knockdown and RPS6 S/D plus ZNF598-knockdown HEK293T cells, with or without anisomycin (ANS), shown over 15–75 nt (h) or 40–75 nt (i); the latter highlights collision-associated footprints. j, Frameshifting with or without ZNF598 knockdown (left), in-frame reporter signal (middle), and frameshifting corrected using the in-frame signal (right). In a and b, “Low” denotes codon pairs with low in-frame rates (bottom 10%, n = 372 pairs) in HCT116 cells. Boxes show the median and 25th–75th percentiles; whiskers extend to the most extreme values within 1.5× the interquartile range, with outliers shown individually. Statistical significance was assessed using a two-sided Wilcoxon rank-sum test. In c, d, f and j, data are mean ± s.d.; n = 3 biologically independent samples. In d and j, two-sided unpaired t-tests were used. In e, western blot was performed twice independently with similar results.
Source data
Extended Data Fig. 7 RPS6 phosphorylation modulates frameshifting and RQC-related responses.
a, Western blot analysis of RPS6 phosphorylation (pRPS6; left) and AKT phosphorylation (pAKT; right) across indicated cancer cell lines. b, Western blot of NMD components and the RQC factor ZNF598 in HEK293, HEK293T, Caco2 and PANC-1 cells. c, Western blot of phosphorylated and total RPS6 and AKT in indicated cell lines. d, Frameshifting activity in HEK293 and HEK293T cells. “Ctrl” denotes a reporter lacking the insert. e, Frameshifting activity in HEK293T cells expressing wild-type or mutant RPS6. f, Sanger sequencing confirming knock-in of RPS6 phospho-site mutations. S/D denotes phospho-mimetic substitution of Ser235, Ser236, Ser240, Ser244 and Ser247 with aspartate in HEK293T cells; S/A denotes substitution of the same residues with alanine in HCT116 cells. g,h, Western blot analysis of mTOR pathway proteins in wild-type and RPS6-S/D HEK293T cells (g) or RPS6-S/A HCT116 cells (h). i, Puromycin-labelling assay of global protein synthesis in RPS6-S/D HEK293T and RPS6-S/A HCT116 cells versus wild-type controls. j, Ribosome-footprint length distributions at low-in-frame-rate codon pairs (bottom 10%, n = 372 pairs) and other pairs in scramble-control or RPS6 S/D-expressing Caco2 cells. Codon-pair groups were defined using the independently identified HEK293T frameshifting-prone set; RPS6 S/D is as defined in f. k, Frameshifting activity in scramble-control and RPS6 S/D-expressing Caco2 cells, with or without ZNF598 knockdown. l, Representative polysome profiles of wild-type and RPS6-S/D HEK293T cells with or without anisomycin (ANS), 24 h after ZNF598 overexpression. In a, western blots were performed twice independently with similar results. In b, c and i, blots show three biologically independent samples per cell line. In g and h, western blots were performed once. In d, e and k, data are mean ± s.d.; n = 3 biologically independent samples. In k, a two-sided unpaired t-test was used.
Source data
Extended Data Fig. 8 FAST induces cell death in vitro.
a, Western blot confirming FAST expression in HCT116 cells using an anti-Flag antibody. “CCAAGT” denotes FAST containing the non-frameshifting motif CCAAGT; “AGAACG” denotes standard FAST. A C-terminal Flag tag was fused to GSDMD-N exclusively for its detection in this experiment. b,c, RT-qPCR analysis of FAST (b) and control transcript (c) stability after UPF1 knockdown. d,e, Representative flow cytometry plots (d) and quantification (e) of HCT116 cell death induced by FAST containing 1×, 3×, 5× or 10× AGAACG repeats; CCAAGT denotes the non-frameshifting control. f, Representative flow cytometry plots of cell death in cancer cells transfected with indicated constructs. g, Frameshifting activity of reporters containing the indicated motifs in PANC-1 cells. h, Representative flow cytometry plots (left) and quantification (right) of PANC-1 cell death induced by FAST containing AGAACG, CCAAGT or ACGAGA. i, Frameshifting activity of the indicated reporters in MC38 cells. “Ctrl” denotes a reporter lacking the insert. j,k, Representative flow cytometry plots (j) and quantification (k) of cell death in MC38 cells using a doxycycline-inducible pTetOne system. CCAAGT denotes the non-frameshifting FAST control; “MC38” denotes parental cells without construct expression. In a, western blot was performed once. In b, c, e, g, h, i and k, data are mean ± s.d.; n = 3 biologically independent samples. In b and c, P values correspond to comparisons at the final time point using a two-sided unpaired t-test.
Source data
Extended Data Fig. 9 Anti-tumour efficacy of FAST in CRC.
a, Top panel shows in vivo experimental design. MC38 tumour-bearing mice carrying the Tet-inducible FAST circuit were treated with intratumoral doxycycline (Dox, PBS as control) and intraperitoneal αPD-L1 antibody. Bottom, tumour growth curves of MC38 syngeneic tumours. b, Representative formalin-fixed MC38 tumours after treatment. c, Representative fluorescence micrographs showing cell death in Dox-treated tumours, with DAPI staining the nuclei. Scale bar, 25 μm. d, Representative immunohistochemical images of tumour immune and inflammatory markers, with hematoxylin staining the nuclei. Scale bar, 200 μm. e, Top panel shows in vivo experimental design. MC38 tumour-bearing mice received intratumoral AAV9-FAST (treatment) or AAV9-FS-Fluc (control), with tumour growth monitored over time. Bottom panel shows tumour volumes. The right panel shows representative images of MC38 tumours with different treatments. FS-Fluc: FAST construct in which GSDMD-N is replaced with firefly luciferase (Fluc), serving as a non-therapeutic control. f, Representative fluorescence micrographs of tumour sections showing cell death in the AAV9-FAST-treated group, with DAPI staining the nuclei. Scale bar, 25 μm. g, Representative immunofluorescence images of tumour sections from AAV9-treated mice, showing co-expression of IFNγ with CD4+ T cells, with DAPI staining the nuclei. Scale bar, 25 μm. h, Representative images of MC38 tumours following intravenous administration of different constructs, related to Fig. 4a in main text. i, Representative flow cytometry analysis of cell death in HCT116 cells expressing different constructs. The right panel shows quantification of cell death across replicates. CCAAGT: FAST construct in which the frameshifting motif AGAACG is replaced with a non-frameshifting motif CCAAGT, serving as a frameshifting-negative control; GSDMDC192A: FAST construct with downstream GSDMD-N carrying the C192A mutation. j, Top panel shows representative images of MC38 tumours following intravenous administration of each construct. The bottom panel shows tumour growth curves comparing the effects of different constructs. Constructs are the same as i. FS-Fluc: FAST construct in which GSDMD-N is replaced with firefly luciferase (Fluc), serving as a non-therapeutic control. k, Representative image of MC38 tumour-bearing mice, related to Fig. 4b in main text. l, Anti-tumour effect of FAST in immunocompromised NSG mice. Top panel shows representative images of HCT116 tumours from NSG mice treated with FAST or the non-therapeutic control construct FS-Fluc. Bottom panel shows tumour growth curves following intravenous injection of FAST or FS-Fluc. In a and e, data are mean ± s.d.; n = 5 mice per group. In i, data are mean ± s.d., two-sided unpaired t-test; n = 3 biologically independent samples. In j and l, data are mean ± s.d., P values correspond to comparisons at the final time point using a two-sided unpaired t-test; n = 6 mice per group. In c, d, f and g, representative images are from n = 3 biologically independent mice per group, with similar results.
Source data
Extended Data Fig. 10 Anti-tumour efficacy of FAST in KPC mice.
a, Representative pancreases from wild-type (WT) and KPC mice at 9 weeks. b, Representative H&E-stained pancreatic sections. Scale bars, 200 μm and 50 μm (high magnification). c, Representative livers from WT and KPC mice at 9 weeks (left) and corresponding H&E-stained sections (right). Scale bars, 200 μm and 50 μm. d, Representative H&E-stained lung sections. Scale bars, 200 μm and 50 μm. e, Representative immunofluorescence images of pancreas stained for Rluc and Fluc, with DAPI staining the nuclei. Scale bar, 25 μm. FS-Fluc denotes a non-therapeutic FAST control in which GSDMD-N is replaced by Fluc. f, Representative pancreases from KPC mice collected at 11 weeks after treatment at 9 weeks. g, Representative H&E-stained pancreatic sections showing tumour pathology. Scale bars, 200 μm and 50 μm. h, Representative immunohistochemical micrographs of paraffin-embedded tumours stained for EpCAM, an epithelial marker commonly expressed in pancreatic neoplastic lesions. The right panel shows the quantification of EpCAM positive area. FS-Fluc: FAST construct in which GSDMD-N is replaced with firefly luciferase, serving as a non-therapeutic control. Scale bars, 200 μm and 50 μm (high magnification). Data are mean± s.d.; n = 5 biologically independent mice per group; three fields of view were analysed per mouse. i, Sytox staining showing cell death in KPC pancreas. Scale bar, 25 μm. FS-Fluc is as in e. j, Representative immunofluorescence images of WT pancreas stained for Rluc and Fluc, with DAPI counterstaining of nuclei. “Fluc” denotes direct Fluc expression as a positive control; FS-Fluc denotes a dual-luciferase reporter with Fluc in the −1 frame. Scale bar, 25 μm. k, Representative Sytox staining of WT pancreas after FAST or FS-Fluc treatment. Constructs are as in i. Scale bar, 25 μm. In b–e and i–k, representative images are from n = 3 biologically independent mice per group, with similar results. In g, representative images are from n = 5 biologically independent mice per group, with similar results.
Source data
Extended Data Fig. 11 FAST induces anti-tumour inflammation in the tumour microenvironment.
a, Representative pancreatic immunofluorescence images showing CD4 with IFNγ and CD8 with IFNγ, with DAPI staining the nuclei. Constructs and treatments are as in Fig. 4h. Scale bar, 25 μm. b, UMAP visualization of cell populations identified by single-cell RNA sequencing in pancreatic tumours treated with FS-Fluc or FAST. FS-Fluc denotes a non-therapeutic FAST control in which GSDMD-N is replaced by Fluc. c, Relative proportions of the indicated cell populations in FS-Fluc- and FAST-treated tumours. d, Representative immunohistochemical images of major organs stained for cytokines and inflammatory factors; nuclei, hematoxylin. “Intestine” refers to small intestine. Constructs are as in b. Scale bar, 25 μm. e, Representative Sytox staining of major tissues from FAST- or FS-Fluc-treated mice. Constructs are as in b. Scale bar, 25 μm. In a, d, and e, representative images are from n = 3 biologically independent mice per group, with similar results.
Extended Data Fig. 12 Safety analysis of FAST IV in KPC mice.
a, Comparison of body weight in KPC mice treated with different constructs. FS-Fluc: FAST construct in which GSDMD-N is replaced with firefly luciferase, serving as a non-therapeutic control; CCAAGT: FAST construct in which the AGAACG motif is replaced with CCAAGT, serving as a frameshifting-negative control. b, Measurement of food intake in KPC mice treated with different constructs. Constructs are the same as a. c, Representative micrographs of paraffin-embedded liver sections stained immunohistochemically for IL-1β, IL-6, and TNF-α, with hematoxylin counterstaining of nuclei. Constructs are the same as a. The right panel shows quantification of immunostaining. Three fields of view were analysed per mouse. Scale bar, 25 μm. KPC mice were used. d, Comparison of the anti-tumour effects of different constructs. Top, representative images of pancreas from KPC mice treated with the indicated constructs. Bottom, pancreas weights of KPC mice in each treatment group. e, Serum levels of key inflammatory cytokines and chemokines of KPC mice quantified by multiplex assay. KC: CXCL1. Constructs are the same as a. f, Serum biomarkers of organ function of KPC mice: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) for liver function; α-amylase (a-AMY) and lipase (LIP) for pancreatic function; creatine kinase (CK) for heart function; creatinine (Cr) for kidney function. Constructs are the same as a. In a, d–f, data are mean ± s.d.; n = 5 mice per group. In c, data are mean ± s.d.; n = 6 mice per group.
Source data
Extended Data Fig. 13 Specificity and safety of FAST under severe nutritional stress.
a, Representative image of wild-type mice subjected to an arginine- and threonine-deficient diet for one (top) or three (bottom) weeks. b, Comparison of body weight of wild-type mice subjected to arginine- and threonine-deficient diet. c, Representative immunofluorescence micrographs of mouse tissues after nutrient deprivation, stained for Rluc and Fluc, with DAPI counterstaining of nuclei. The control and nutrient-deprivation groups were from the same experiment and processed in parallel. The results from Fluc positive-control condition and the 3-week FS-Fluc control condition were also presented in Fig. 5b; the same representative images, other than the small intestine, are shown here alongside the corresponding nutrient-deprivation groups for comparison. FS-Fluc denotes a dual-luciferase reporter with Fluc placed in the −1 frame. “Intestine” refers to small intestine. Scale bar, 25 μm. d, Representative immunohistochemical images of IL-1β, IL-6 and TNF-α in liver sections from mice in the indicated treatment groups. Scale bar, 25 μm. Bar plots on the right show the corresponding quantification of the IHC-positive area. Three fields of view were analysed per mouse. FAST (complete diet) mice were treated with FAST and maintained on a nutritionally complete diet. FS-Fluc (Arg/Thr-deficient) and FAST (Arg/Thr-deficient) mice were treated with the corresponding construct and maintained on an Arg/Thr-deficient diet for 3 weeks. FAST (refed) mice were treated with FAST and maintained on an Arg/Thr-deficient diet for 3 weeks, after which they were returned to a nutritionally complete diet for 5 days. e, Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in the indicated groups. In b, d and e, data are mean ± s.d.; n = 5 mice per group. In c, representative images are from n = 2 biologically independent mice per group, with similar results.
Source data
Supplementary information
Source data
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Reprints and permissions
About this article
[Check for updates. Verify currency and authenticity via CrossMark]
Cite this article
Wang, Q., Chen, A., Liu, Y. et al. Cancer-selective gene circuits via intrinsic ribosomal frameshifting. Nature (2026). https://doi.org/10.1038/s41586-026-11200-4
Download citation
Received: 28 October 2025
Accepted: 22 September 2026
Published: 04 November 2026
Version of record: 04 November 2026
DOI: https://doi.org/10.1038/s41586-026-11200-4